FTC Demands Drug Divestment For $1.9B Mylan, Agila Merger

Law360, Los Angeles (September 26, 2013, 9:23 PM ET) -- The Federal Trade Commission on Thursday said it will require Mylan Inc. and Agila Specialties Global Ltd. to divest 11 of their generic injectable drugs if they want to complete their $1.9 billion merger.

In each market for the 11 drugs, the two pharmaceutical companies are the only maker of the generics, the FTC said in a proposed consent order Thursday. Such poses two problems for the agency. First, the lack of competition could force the prices of the drugs to rise. Second, the supply of...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required